- Voyager Therapeutics (NASDAQ:VYGR): Q3 GAAP EPS of $2.27.
- Collaboration revenue of $117.84M (+476.8% Y/Y).
- Cash, cash equivalents and marketable debt of of $200M.
- Press Release
- https://seekingalpha.com/news/3633989-voyager-therapeutics-reports-q3-results
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.